Monday, January 25, 2016 3:25:02 PM
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal?
News Release Issued: Jan 25, 2016 (11:41am MST)
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
CALGARY, Jan 25, 2016 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced the acceptance for publication of a manuscript titled: "RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease," in the journal "Atherosclerosis".
The key information in the manuscript details some of the beneficial actions of apabetalone (RVX-208), a bromodomain extra-terminal (BET) protein inhibitor for treating high-risk cardiovascular disease (CVD) patients. The data presented emphasises not only that apabetalone (RVX-208) raises the levels of ApoA-I and HDL, but also that the epigenetic actions of this BET inhibitor can modulate several factors known to be major contributors to CVD risk.
Dr. Norman C.W. Wong, chief scientific officer of Resverlogix stated, "We are pleased to have our data peer reviewed and published in the Atherosclerosis journal. This additional recognition helps to further confirm the importance of epigenetics in successfully modulating key CVD pathways."
The accepted manuscript is currently in electronic press and will appear in a future print issue of Atherosclerosis. An online version of the manuscript can be accessed at:
http://www.atherosclerosis-journal.com/article/S0021-9150(16)30035-1/fulltext
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM